Chrisann Kyi

2.2k total citations
41 papers, 1.3k citations indexed

About

Chrisann Kyi is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Chrisann Kyi has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Chrisann Kyi's work include Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (12 papers) and Immunotherapy and Immune Responses (12 papers). Chrisann Kyi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (12 papers) and Immunotherapy and Immune Responses (12 papers). Chrisann Kyi collaborates with scholars based in United States, Spain and Netherlands. Chrisann Kyi's co-authors include Michael A. Postow, Michael A. Postow, Jedd D. Wolchok, María del Carmen López Castillo, Gil Redelman‐Sidi, Fabián Andrés Rosas Romero, Richard D. Carvajal, Matthew D. Hellmann, Paul B. Chapman and Philip Friedlander and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Chrisann Kyi

36 papers receiving 1.3k citations

Peers

Chrisann Kyi

ONCOL

IMMUN

PRM

EPIDE

Markus Hecht Germany

Alain Gey France

Maike Buettner Germany

Silvia Spoerl Germany

Sayuri Miyauchi United States

Deborah Jean Lee Wong United States

Takumi Kumai Japan

Nathanael G. Bailey United States

Carlos Grande Spain

Markus Hecht Germany

Chrisann Kyi

891 ×0.9

ONCOL

336 ×0.6

IMMUN

370 ×1.8

289 ×1.4

PRM

68 ×0.4

EPIDE

Citations per year, relative to Chrisann Kyi Chrisann Kyi (= 1×) peers Markus Hecht

Countries citing papers authored by Chrisann Kyi

Since Specialization

Citations

This map shows the geographic impact of Chrisann Kyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chrisann Kyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chrisann Kyi more than expected).

Fields of papers citing papers by Chrisann Kyi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chrisann Kyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chrisann Kyi. The network helps show where Chrisann Kyi may publish in the future.

Co-authorship network of co-authors of Chrisann Kyi

This figure shows the co-authorship network connecting the top 25 collaborators of Chrisann Kyi. A scholar is included among the top collaborators of Chrisann Kyi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chrisann Kyi. Chrisann Kyi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johannet, Paul, M. Herman Chui, Jason Konner, et al.. (2025). Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate. Gynecologic Oncology. 195. 173–179.

Iasonos, Alexia, Qin Zhou, Jeffrey Girshman, et al.. (2025). Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary. International Journal of Gynecological Cancer. 35(1). 100005–100005.

Kyi, Chrisann, Sylvie Rottey, Ignacio Melero, et al.. (2024). Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2520–2520. 4 indexed citations

MacLaughlan, Shannon, Daniela Matei, Min Ji Song, et al.. (2024). 744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296). Annals of Oncology. 35. S564–S565. 1 indexed citations

Lumish, Melissa, M. Herman Chui, Qin Zhou, et al.. (2024). A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). Gynecologic Oncology. 182. 75–81. 7 indexed citations

Iasonos, Alexia, Qin Zhou, Jeffrey Girshman, et al.. (2024). Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer. Gynecologic Oncology. 189. 30–36. 2 indexed citations

Zhou, Qin, Alexia Iasonos, Oliver Zivanovic, et al.. (2024). Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series. International Journal of Gynecological Cancer. 34(4). 594–601. 1 indexed citations

Peraro, Leila, Tatyana Korontsvit, Thomas J. Gardner, et al.. (2023). Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunology Immunotherapy. 72(11). 3773–3786. 20 indexed citations

Ferris, Robert L., William C. Spanos, Rom S. Leidner, et al.. (2021). Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. Journal for ImmunoTherapy of Cancer. 9(6). e002568–e002568. 126 indexed citations

10.

Prenen, Hans, Chrisann Kyi, Sandip Pravin Patel, et al.. (2021). 136P Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors. Annals of Oncology. 32. S1436–S1436. 7 indexed citations

11.

Miller, Kathryn, Olga T. Filippova, Sara A. Hayes, et al.. (2021). Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecologic Oncology Reports. 37. 100831–100831. 6 indexed citations

12.

Dao, Tao, Martin G. Klatt, Tatyana Korontsvit, et al.. (2020). Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology Immunotherapy. 70(5). 1189–1202. 8 indexed citations

13.

Drake, Charles G., Melissa L. Johnson, Alexander I. Spira, et al.. (2020). Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.. Journal of Clinical Oncology. 38(15_suppl). 3137–3137. 8 indexed citations

14.

Rubinstein, Maria M., Rachel N. Grisham, Karen A. Cadoo, et al.. (2020). A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecologic Oncology. 160(1). 71–76. 9 indexed citations

15.

Kyi, Chrisann, Vladimir Roudko, Rachel Lubong Sabado, et al.. (2018). Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. Clinical Cancer Research. 24(20). 4937–4948. 97 indexed citations

16.

Friedlander, Philip, David E. Fisher, Chrisann Kyi, et al.. (2017). Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. Journal for ImmunoTherapy of Cancer. 5(1). 67–67. 34 indexed citations

17.

Castillo, María del Carmen López, et al.. (2016). The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clinical Infectious Diseases. 63(11). 1490–1493. 226 indexed citations

18.

Kyi, Chrisann, Richard D. Carvajal, Jedd D. Wolchok, & Michael A. Postow. (2014). Ipilimumab in patients with melanoma and autoimmune disease. Journal for ImmunoTherapy of Cancer. 2(1). 35–35. 75 indexed citations

19.

Kitano, Shigehisa, Takemasa Tsuji, Daniel Hirschhorn-Cymerman, et al.. (2013). Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunology Research. 1(4). 235–244. 96 indexed citations

20.

Kyi, Chrisann & Michael A. Postow. (2013). Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters. 588(2). 368–376. 194 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact